ClinicalTrials.gg
TerminatedNCT00437073Updated Oct 15, 2015Results posted

Brain Metastases In ErbB2-Positive Breast Cancer

A Phase 2 interventional study of capecitabine and topotecan in Neoplasms, Breast, sponsored by GlaxoSmithKline. Terminated at 44 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-15.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Why this study was terminated
Lapatinib-topotecan arm enrollment closed early per protocol amendment 2. Then enrollment into remaining arm terminated due to operational issues.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.

Enrollment
182nd of 227
22 · median 54
Started
2007
with 13 others
Phase 2
121 of 233
20 open now
Registered
73rd of 233
by date

Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 182nd largest by enrollment of the 227 interventional ones that give a count, is one of 14 that started in 2007, is one of 121 in phase 2, and was the 73rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies testing capecitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

This study is for patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic radiosurgery) to the brain. The study will determine how safe and effective lapatinib is when given in combination with capecitabine to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain. Lapatinib is an oral drug that will be taken every day. Tests for safety and efficacy will be performed regularly during the course of the study.

03

Conditions studied

  • Neoplasms, Breast

Keywords

  • brain metastases
  • ErbB2
  • lapatinib
  • Breast Cancer
  • HYCAMTIN
  • topotecan
  • capecitabine
  • metastatic breast cancer
  • TYKERB
  • XELODA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible for enrollment in the study must meet all of the following criteria:

  • Signed written ;
  • Females or males age ≥ 18 years old;
  • (ECOG) Performance Status 0-1;
  • of at least 12 weeks;
  • Subjects must have or cytologically confirmed invasive breast cancer, with Stage IV disease;
  • ErbB2 overexpressing breast cancer, defined as 3+ staining by immunohistochemistry (IHC), or 2+ staining by IHC in conjunction with ErbB 2 gene amplification by FISH, or ErbB 2 gene amplification by FISH alone (in subjects whose tumor blocks were not assessed by IHC). Subjects with tumors that are 2+ by IHC but negative or borderline by FISH assay are ineligible. For subjects with a history of more than one primary breast cancer, each breast cancer must be ErbB2 overexpressing to be eligible;
  • ErbB2 overexpressing breast cancer, defined as 3+ staining by immunohistochemistry (IHC), or 2+ staining by IHC in conjunction with ErbB2 gene amplification by FISH, or ErbB2 gene amplification by FISH alone (in subjects whose tumor blocks were not assessed by IHC). ErbB2 gene amplification is defined by: > 6 ErbB2 gene copies/nucleus for test systems without an internal control probe or an ErbB2/CEP 17 ratio of more than 2.2. Subjects with tumors that are 2+ by IHC but negative or borderline by FISH assay are ineligible. For subjects with a history of more than one primary breast cancer, each breast cancer must be ErbB2 overexpressing to be eligible;
  • Prior treatment of with WBRT and/or SRS;
  • Unequivocal evidence of new and / or progressive lesions in the brain on an imaging study; Note: Subjects with progressive brain lesions are not required to meet criteria for CNS progression in order to be eligible for this study.
  • Prior treatment with trastuzumab, either alone or in combination with chemotherapy is required. Trastuzumab will be discontinued at least 2 weeks prior to enrollment on study;
  • Cardiac within institutional range of normal as measured by echocardiogram. Subjects who require cardiac medications (e.g. positive inotropic agents or afterload reducers) for normal ejection fraction are ineligible. MUGA scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive;
  • At least 2 weeks since prior radiotherapy, last chemotherapy, immunotherapy, biologic therapy, or hormonal therapy for cancer, and sufficiently recovered or stabilized from side effects associated with prior therapy. Concurrent treatment with bisphosphonates is permitted;
  • At least 3 weeks since major surgical procedures;
  • Able to swallow and retain oral medications;
  • Women of must have a negative serum pregnancy test at screening and must use an approved method, if appropriate (for example, intrauterine device [IUD], birth control pills, or barrier device) beginning 2 weeks before the first dose of product and for 28 days after the final dose of investigational product. Males able to father a child must practice adequate methods of birth control or practice complete abstinence from intercourse from the first dose of investigational treatment until one week after the final dose of investigational treatment.
  • Subjects must complete all screening assessments as outlined in the protocol;
  • Normal organ and marrow function as defined by these LABORATORY VALUES : (absolute neutrophil count) ≥ 1.5 x 10\^9/L; ≥ 10 g/dL (after transfusion if needed); ≥ 100 x 10\^9/L; Albumin ≥ 2.5 g/dL; Serum ≤ 1.5x unless due to Gilbert's syndrome; and ALT ≤ 5x ULN if documented liver ≤ 3x ULN without liver metastases; Serum Creatinine ≤ 1.2 mg/dL or Calculated Creatinine Clearance1 ≥ 50 mL/min

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

  • Subjects who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or who have unresolved or unstable, serious toxicity from prior administration of another drug and/or of prior cancer treatment;
  • Concurrent treatment with an investigational agent or participation in another treatment clinical trial;
  • Prior therapy with a topoisomerase 1 inhibitor;
  • Prior lapatinib therapy;
  • Prior therapy with capecitabine;
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency;
  • Performance Status 2 or greater;
  • Subjects receiving concurrent chemotherapy, radiation therapy, immunotherapy, biologic therapy (including an ErbB1 and/or ErbB2 inhibitor), or hormonal therapy for treatment of their cancer. Hormone therapy for ovarian suppression which has been used for > 6 months, during which time there has been disease progression in the brain, is allowed. Concurrent treatment with bisphosphonates is allowed;
  • Subjects with evidence of at screening;
  • History of allergic reactions attributed to compounds of similar chemical composition (quinazolines) to lapatinib;
  • History of allergic reactions attributed to compounds chemically related to capecitabine, fluorouracil or any ;
  • Concurrent treatment with medications listed as Prohibited Medications;
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with active, uncontrolled ulcerative colitis are also excluded;
  • History of immediate or delayed reaction to gadolinium contrast agents, or other to gadolinium contrast;
  • Other known contraindication to MRI, such as a cardiac pacemaker, implanted cardiac defibrillator, brain aneurysm clips, cochlear implant, ocular foreign body, or shrapnel;
  • Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety;
  • Anticoagulant therapy (other than coumadin or aspirin as catheter prophylaxis) at study entry;
  • Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of , unless a legally acceptable representative could provide informed consent (if in accord with the policies of the local Ethics Committee);
  • Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel, CNS vasculitis, or malignant hypertension;
  • Active cardiac disease, defined as one or more of the following:
  • History of uncontrolled or symptomatic angina
  • History of arrhythmias requiring medications, or
  • Myocardial infarction \< 6 months from study entry
  • Uncontrolled or symptomatic congestive heart failure
  • below the institutional normal limit
  • Any other cardiac condition, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient;
  • Uncontrolled infection;
  • Pregnant or lactating females;
  • History of other , except for curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix. Subjects with other malignancies who have been disease-free for at least 5 years are eligible.
  • Have current active hepatic or biliary disease (with exception of subjects with Gilbert's syndrome, asymptomatic gallstones, liver or stable chronic liver disease per investigator assessment).
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    lapatinib plus capecitabine

    A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.

    Drug: capecitabine · Drug: lapatinib

  • Experimental
    lapatinib + topotecan

    A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.

    Drug: topotecan · Drug: lapatinib

Interventions

  • capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days

    Also known as: Xeloda

  • topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days

    Also known as: Hycamtin

  • lapatinib administered 1250mg once daily orally

    Also known as: Tykerb/Tyverb

06

What researchers measure

Primary outcomes

  1. Number of Participants With the Indicated Central Nervous System (CNS) Objective Response (OR)

    CNS OR is defined as the number of participants with either a complete response (CR) or partial response (PR) as assessed by volumetric analysis of brain magnetic resonance imaging (MRI) and Response Evaluation Criteria In Solid Tumors (RECIST). CR: complete resolution of all evaluable and non-evaluable brain metastases; PR: =\>50% reduction in the volumetric sum of all evaluable brain metastases compared to baseline.

    Time frame: From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

  2. Number of Participants With the Indicated CNS Responses

    CNS responses were assessed by volumetric (V) analysis of brain MRI and RECIST. CR: complete resolution of all evaluable and non-evaluable brain metastases (BMs). PR: =\>50% reduction in the V sum of all evaluable BMs compared to baseline. A response of "Other" was used for participants who discontinued the study prior to the first efficacy assessment. Stable Disease (SD): disease that does not meet CR, PR, or CNS progression criteria. Progressive disease (PD): a requirement for a new steroid or an increasing steroid dose for the treatment of worsening neurological signs/symptoms due to BMs.

    Time frame: From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

Secondary outcomes

  1. Duration of CNS Objective Response (Defined as the Time From the First Documented Evidence of CNS PR or CR Until the First Documented Sign of Disease Progression or Death, if Sooner)

    CNS OR is defined as the number of participants with either a CR or PR as assessed by volumetric analysis of brain MRI and RECIST. CR: complete resolution of all evaluable and non-evaluable brain metastases; PR: =\>50% reduction in the volumetric sum of all evaluable brain metastases compared to baseline. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

    Time frame: From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

  2. Percentage of Participants With Clinical Benefit

    Clinical benefit is defined as CR (complete resolution of all evaluable and non-evaluable brain metastases), PR (=\>50% reduction in the volumetric sum of all evaluable brain metastases compared to baseline), or stable disease (disease that does not meet CR, PR, or CNS progression criteria) for at least 6 months. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

    Time frame: From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

  3. Percentage of Participants (Par.) With Objective Response by RECIST in Non-CNS Disease

    Non-CNS disease (for par. with measurable baseline non-CNS disease) OR is defined as the number of par. with either a CR or PR as assessed by computed tomography (CT) or MRI scan and RECIST. CR: disappearance of all target lesions; PR: at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough par. enrolled in the study to provide statistically valid analyses.

    Time frame: From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

  4. Time to CNS Objective Response (Defined as the Time From the Start of Treatment Until the First Documented Evidence of Partial or Complete Tumor Response [Whichever Status is Recorded First])

    CNS OR is defined as the number of participants with either a CR or PR as assessed by volumetric analysis of brain MRI and RECIST. CR: complete resolution of all evaluable and non-evaluable brain metastases; PR: =\>50% reduction in the volumetric sum of all evaluable brain metastases compared to baseline. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

    Time frame: From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

  5. Number of Participants With the Indicated Site of Initial Disease Progression

    The site of initial disease will be determined by taking the earliest date of known progression and assigning the appropriate category (CNS or non-CNS) based on the source of the earliest date. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

    Time frame: From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

  6. Progression-free Survival

    Progression-free survival is defined as the time from the start of treatment until the first documented sign of disease progression at any site or death due to any cause, if sooner. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

    Time frame: From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

  7. Overall Survival

    Overall survival is defined as the time from the start of treatment until death due to any cause. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

    Time frame: From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

  8. Percentage of Participants With Baseline Tumor-related (TR) Neurological Signs and Symptoms (NSS), Who Experienced Improvement in NSS as Measured by the Neurological Examination Worksheet (NEW)

    TR NSS was to be recorded by the Investigator on the NEW, using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE V3.0). Improvement was to be defined as a decrease of 1 or more CTCAE grades from baseline of any TR NSS. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

    Time frame: From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

  9. Percentage of Participants With Disease Stabilization for 6 Months or More

    The percentage participants with disease stabiliztion for 6 months or more were defined as those treated participants with a best CNS objective response of SD whose disease stabilization lasted 6 months or more from the start of treatment. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

    Time frame: From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

  10. Percentage of Participants With a >=20% Volumetric Reduction in CNS Lesions

    The percentage of participants with a \>=20% volumetric reduction in CNS lesions was defined as the percentage of treated participants achieving at least a 20% volumetric reduction in CNS lesions relative to baseline. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

    Time frame: Baseline; from the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

07

Results

Posted Oct 15, 2012

Participant flow

Participant flow — Overall Study
MilestoneLapatinib Plus CapecitabineLapatinib Plus Topotecan
Started139
Completed128
Not completed11
Withdrew: Sponsor terminated study10
Withdrew: Physician decision01

Outcome measures

PrimaryNumber of Participants With the Indicated Central Nervous System (CNS) Objective Response (OR)

CNS OR is defined as the number of participants with either a complete response (CR) or partial response (PR) as assessed by volumetric analysis of brain magnetic resonance imaging (MRI) and Response Evaluation Criteria In Solid Tumors (RECIST). CR: complete resolution of all evaluable and non-evaluable brain metastases; PR: =\>50% reduction in the volumetric sum of all evaluable brain metastases compared to baseline.

Time frame:
From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88
Reported as:
Number · participants
Number of Participants With the Indicated Central Nervous System (CNS) Objective Response (OR)
participantsLapatinib Plus CapecitabineLapatinib Plus Topotecan
Number of Participants With the Indicated Central Nervous System (CNS) Objective Response (OR)50
Statistical analysis
  • Lapatinib Plus Capecitabine · Percentage of participants: 38 · 95% CI 13.9 to 68.4The estimated value indicates the percentage of participants with CNS OR in the Lapatinib plus Capecitabine treatment arm.
PrimaryNumber of Participants With the Indicated CNS Responses

CNS responses were assessed by volumetric (V) analysis of brain MRI and RECIST. CR: complete resolution of all evaluable and non-evaluable brain metastases (BMs). PR: =\>50% reduction in the V sum of all evaluable BMs compared to baseline. A response of "Other" was used for participants who discontinued the study prior to the first efficacy assessment. Stable Disease (SD): disease that does not meet CR, PR, or CNS progression criteria. Progressive disease (PD): a requirement for a new steroid or an increasing steroid dose for the treatment of worsening neurological signs/symptoms due to BMs.

Time frame:
From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88
Reported as:
Number · participants
Number of Participants With the Indicated CNS Responses
participantsLapatinib Plus CapecitabineLapatinib Plus Topotecan
Complete response00
Partial response50
Stable Disease63
Progressive Disease21
Unknown03
Other02
SecondaryDuration of CNS Objective Response (Defined as the Time From the First Documented Evidence of CNS PR or CR Until the First Documented Sign of Disease Progression or Death, if Sooner)

CNS OR is defined as the number of participants with either a CR or PR as assessed by volumetric analysis of brain MRI and RECIST. CR: complete resolution of all evaluable and non-evaluable brain metastases; PR: =\>50% reduction in the volumetric sum of all evaluable brain metastases compared to baseline. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

Time frame:
From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Clinical Benefit

Clinical benefit is defined as CR (complete resolution of all evaluable and non-evaluable brain metastases), PR (=\>50% reduction in the volumetric sum of all evaluable brain metastases compared to baseline), or stable disease (disease that does not meet CR, PR, or CNS progression criteria) for at least 6 months. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

Time frame:
From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

No measurements were reported for this outcome.

SecondaryPercentage of Participants (Par.) With Objective Response by RECIST in Non-CNS Disease

Non-CNS disease (for par. with measurable baseline non-CNS disease) OR is defined as the number of par. with either a CR or PR as assessed by computed tomography (CT) or MRI scan and RECIST. CR: disappearance of all target lesions; PR: at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough par. enrolled in the study to provide statistically valid analyses.

Time frame:
From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

No measurements were reported for this outcome.

SecondaryTime to CNS Objective Response (Defined as the Time From the Start of Treatment Until the First Documented Evidence of Partial or Complete Tumor Response [Whichever Status is Recorded First])

CNS OR is defined as the number of participants with either a CR or PR as assessed by volumetric analysis of brain MRI and RECIST. CR: complete resolution of all evaluable and non-evaluable brain metastases; PR: =\>50% reduction in the volumetric sum of all evaluable brain metastases compared to baseline. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

Time frame:
From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

No measurements were reported for this outcome.

SecondaryNumber of Participants With the Indicated Site of Initial Disease Progression

The site of initial disease will be determined by taking the earliest date of known progression and assigning the appropriate category (CNS or non-CNS) based on the source of the earliest date. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

Time frame:
From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

No measurements were reported for this outcome.

SecondaryProgression-free Survival

Progression-free survival is defined as the time from the start of treatment until the first documented sign of disease progression at any site or death due to any cause, if sooner. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

Time frame:
From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival is defined as the time from the start of treatment until death due to any cause. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

Time frame:
From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Baseline Tumor-related (TR) Neurological Signs and Symptoms (NSS), Who Experienced Improvement in NSS as Measured by the Neurological Examination Worksheet (NEW)

TR NSS was to be recorded by the Investigator on the NEW, using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE V3.0). Improvement was to be defined as a decrease of 1 or more CTCAE grades from baseline of any TR NSS. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

Time frame:
From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Disease Stabilization for 6 Months or More

The percentage participants with disease stabiliztion for 6 months or more were defined as those treated participants with a best CNS objective response of SD whose disease stabilization lasted 6 months or more from the start of treatment. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

Time frame:
From the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

No measurements were reported for this outcome.

SecondaryPercentage of Participants With a >=20% Volumetric Reduction in CNS Lesions

The percentage of participants with a \>=20% volumetric reduction in CNS lesions was defined as the percentage of treated participants achieving at least a 20% volumetric reduction in CNS lesions relative to baseline. This study was closed before full enrollment was achieved; thus, predefined secondary efficacy endpoints were not assessed because there were not enough participants enrolled in the study to provide statistically valid analyses.

Time frame:
Baseline; from the start of treatment until disease progression, death, or discontinuation from the study, up to a maximum of Week 88

No measurements were reported for this outcome.

Adverse events

Collected over All serious and non-serious on-therapy adverse events, defined as occurring from the first dose of investigational product until five days after the last dose (up to Week 37) were recorded, regardless of whether or not they were considered drug related.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lapatinib Plus Capecitabine—6/13 (46.2%)13/13 (100%)
Lapatinib Plus Topotecan—5/9 (55.6%)9/9 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventLapatinib Plus CapecitabineLapatinib Plus Topotecan
SepsisInfections and infestations0/132/9
DiarrhoeaGastrointestinal disorders2/131/9
General physical health deteriorationGeneral disorders1/131/9
Urinary tract infectionInfections and infestations0/131/9
DehydrationMetabolism and nutrition disorders0/131/9
HypokalaemiaMetabolism and nutrition disorders1/131/9
SyncopeNervous system disorders0/131/9
ConstipationGastrointestinal disorders1/130/9
Multi-organ failureGeneral disorders1/130/9
PyrexiaGeneral disorders1/130/9
Most frequent other events
Showing 10 of 121
Most frequent other events
EventLapatinib Plus CapecitabineLapatinib Plus Topotecan
DiarrhoeaGastrointestinal disorders11/138/9
FatigueGeneral disorders8/135/9
Palmar-Plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders8/131/9
NauseaGastrointestinal disorders3/135/9
ThrombocytopeniaBlood and lymphatic system disorders1/135/9
HeadacheNervous system disorders6/133/9
Oedema peripheralGeneral disorders5/130/9
RashSkin and subcutaneous tissue disorders5/131/9
AnaemiaBlood and lymphatic system disorders1/133/9
NeutropeniaBlood and lymphatic system disorders1/133/9

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Lapatinib Plus CapecitabineLapatinib Plus TopotecanTotal
Mean49.4 ± 9.2954.6 ± 10.5451.5 ± 9.92
Sex: Female, Male
Sex: Female, Male(Participants)Lapatinib Plus CapecitabineLapatinib Plus TopotecanTotal
Female13922
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lapatinib Plus CapecitabineLapatinib Plus TopotecanTotal
White13922
08

Study locations

44 sites
  • GSK Investigational Site
    Washington, District of Columbia 20007, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Sioux City, Iowa 51101-1733, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55455, United States
  • GSK Investigational Site
    Rochester, Minnesota 55905, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87131-0001, United States
  • GSK Investigational Site
    Cary, North Carolina 27518, United States
  • GSK Investigational Site
    Portland, Oregon 97239, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Salzburg, A-5020, Austria
  • GSK Investigational Site
    Vienna, A-1090, Austria
  • GSK Investigational Site
    Bruxelles, 1000, Belgium
  • GSK Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • GSK Investigational Site
    Quebec, G1S 4L8, Canada
  • GSK Investigational Site
    Besançon, 25030, France
  • GSK Investigational Site
    Lille Cedex, 59020, France
  • GSK Investigational Site
    Paris Cedex 5, 75248, France
  • GSK Investigational Site
    Paris, 75010, France
  • GSK Investigational Site
    Saint-Herblain, 44805, France
  • GSK Investigational Site
    Muenchen, Bayern 80637, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81377, Germany
  • GSK Investigational Site
    Frankfurt am Main, Hessen 60590, Germany
  • GSK Investigational Site
    Troisdorf, Nordrhein-Westfalen 53840, Germany
  • GSK Investigational Site
    Bremen, 28205, Germany
  • GSK Investigational Site
    Heraklion, Crete, 71110, Greece
  • GSK Investigational Site
    Neo Faliro, 18547, Greece
  • GSK Investigational Site
    Petach Tikva, 49100, Israel
  • GSK Investigational Site
    Ramat Gan, 52621, Israel
  • GSK Investigational Site
    Zrifin, 70300, Israel
  • GSK Investigational Site
    Milano, Lombardia 20141, Italy
  • GSK Investigational Site
    Perugia, Umbria 06156, Italy
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Hospitalet de Llobregat, Barcelona, 08907, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Pamplona, 31008, Spain
  • GSK Investigational Site
    Santiago de Compostela, 15706, Spain
  • GSK Investigational Site
    Valencia, 46010, Spain
  • GSK Investigational Site
    Uppsala, SE-751 85, Sweden
09

References and documents

Publications

  • Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, Lane SR, Zembryki D, Rubin SD, Winer EP. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol. 2011 Dec;105(3):613-20. doi: 10.1007/s11060-011-0629-y. Epub 2011 Jun 26. PubMed 21706359 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Jan 2009 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2007
First posted
Feb 19, 2007
Start
May 2007
Primary completionActual
Jan 2009
CompletionActual
Feb 2010
Results first posted
Oct 15, 2012
Last update
Oct 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00437073
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 19, 2007
Start date
May 2007
Primary completion
Jan 2009
Completion
Feb 2010
Results posted
Oct 15, 2012
Last update
Oct 15, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Topotecan

Start the discussion